A cost-based-plus pricing approach for repurposed tiratricol in the treatment of Allan-Herndon-Dudley syndrome

Abstract Background Tiratricol, an old thyroid drug, has been repurposed as an orphan drug for Allan-Herndon-Dudley syndrome, a rare genetic disorder affecting thyroid hormone transport. Despite public contributions to its repurposing, the current marketing authorization holder, Egetis Therapeutics,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Evert Manders, Sarai Keestra, Wilbert Bannenberg, Vincent van der Wel, Saco de Visser, Carla Hollak
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2026-03-01
Col·lecció:	Orphanet Journal of Rare Diseases
Matèries:	Drug repurposing Tiratricol Allan-Herndon-Dudley syndrome MCT8-defficiency Drug pricing
Accés en línia:	https://doi.org/10.1186/s13023-026-04269-7
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!